Chris Oomen

Chris Oomen is a significant shareholder in Kuros Biosciences, holding nearly a quarter of the company's stock through his investment company Optiver. His involvement is crucial as Kuros navigates its growth trajectory and potential acquisition interests from larger firms like Medtronic.